Datapoint: Yescarta Scores Follicular Lymphoma Nod

The FDA on March 5 approved Gilead Sciences’ Yescarta for the treatment of relapsed or refractory follicular lymphoma in patients that have not responded to at least two prior treatments, a feat unmatched by its CAR-T rivals Kymriah and Breyanzi. Under the medical benefit, Yescarta is covered for 32% of all insured lives for the treatment of diffuse large B-cell lymphoma. A further 41% of covered lives have medical benefit access to Yescarta with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/10/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 26

Datapoint: Oscar Partners With Colorado Health Systems in Statewide Expansion Effort

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today